Page last updated: 2024-09-04

torcetrapib and 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin

torcetrapib has been researched along with 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin in 1 studies

Compound Research Comparison

Studies (torcetrapib)	Trials (torcetrapib)	Recent Studies (post-2010) (torcetrapib)	Studies (3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin)	Trials (3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin)	Recent Studies (post-2010) (3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin)
273	28	83	123	9	11

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Powell, JT	1

Other Studies

1 other study(ies) available for torcetrapib and 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin

Article	Year
Three drug indications for patients with peripheral arterial disease bite the dust: report from the American Heart Association meeting 2007 in Orlando. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2008, Volume: 35, Issue:1 Topics: Adrenergic beta-Antagonists; American Heart Association; Anti-Bacterial Agents; Anticholesteremic Agents; Humans; Metoprolol; Peripheral Vascular Diseases; Practice Guidelines as Topic; Quinolines; Rifamycins; United States	2008

Article

Year

Three drug indications for patients with peripheral arterial disease bite the dust: report from the American Heart Association meeting 2007 in Orlando.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2008, Volume: 35, Issue:1

Topics: Adrenergic beta-Antagonists; American Heart Association; Anti-Bacterial Agents; Anticholesteremic Agents; Humans; Metoprolol; Peripheral Vascular Diseases; Practice Guidelines as Topic; Quinolines; Rifamycins; United States

2008